Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128418 | 0.80 | NOS3 (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL20840575 | 0.77 | ALDH1A1 (0.50) | SMN1; SMN2KDM4ETDP1ALDH1A1KMT2A | |
| SCHEMBL8551633 | 0.77 | SMN1; SMN2 (0.35) | SMN1; SMN2KDM4ETDP1KMT2A | |
| SCHEMBL11070549 | 0.77 | — | — | |
| SCHEMBL9310993 | 0.77 | NOS2 (0.46) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL22312575 | 0.76 | SMN1; SMN2 (0.34) | SMN1; SMN2KDM4ETDP1ALDH1A1KMT2A | |
| SCHEMBL11362095 | 0.76 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2A | |
| SCHEMBL125608 | 0.75 | — | — | |
| SCHEMBL20840536 | 0.75 | PRMT6 (0.31) | SMN1; SMN2KDM4E | |
| SCHEMBL11514300 | 0.75 | ALDH1A1 (0.46) | SMN1; SMN2KDM4ETDP1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396501-B2 | Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| EP-3687540-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CGeneTech (Suzhou, China) Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| WO-2019060860-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019060860-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2019-03-28 | — | — | WO | disclosed |
| EP-0714393-B1 | THIAZOLES AS ANTIVIRAL | PFIZER (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5789408-A | Antiviral thiazoles | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0714393-A1 | THIAZOLES AS ANTIVIRAL | PFIZER INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995005378-A1 | ANTIVIRAL THIAZOLES | PFIZER INC. (US) | 1995-02-23 | — | — | WO | disclosed |
| EP-0114045-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS PESTICIDES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-09-03 | — | — | EP | disclosed |
| US-4584295-A | Pyrimidylmethyl thiophosphorus esters useful for the control of insects, mites and nematodes | HOFFMANN-LA ROCHE INC. (US) | 1986-04-22 | — | — | US | disclosed |
| EP-0114045-A1 | Pyrimidine derivatives and their use as pesticides | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-07-25 | — | — | EP | disclosed |
| US-4168304-A | ARTHROPODICIDES, NEMATOCIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1979-09-18 | — | — | US | disclosed |
| US-3941786-A | Process for the production of 4-hydroxy-6-hydroxymethylpyrimidine | LONZA LTD. (CH) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396501-B2 | Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same | CXCR4, CXCL12, CXCR1 | SMN1; SMN2 2758/4885KDM4E 4466/4885TDP1 4045/4885 |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CXCR4, CXCL12, CXCR1 | SMN1; SMN2 2758/4885KDM4E 4466/4885TDP1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.